Literature DB >> 25825961

Circulating serum-derived microparticles provide novel proteomic biomarkers of spontaneous preterm birth.

Alan M Ezrin1, Brian Brohman2, Jackie Willmot3, Sarah Baxter4, Keith Moore5, Mike Luther6, Michael R Fannon7, Baha Sibai8.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether the proteomic biosignature of circulating microparticles in maternal serum obtained in the second trimester could identify pregnancies that result in spontaneous preterm birth (SPTB). STUDY
DESIGN: Microparticles were isolated from blinded biorepository-sourced serum samples from 48 pregnant women at 15 to 17 weeks of gestation. Microparticle proteins were extracted and analyzed using label-free liquid chromatography/mass spectrometry. Peptide features were analyzed to assess the association of specific protein patterns with subjects delivering at term (≥ 37 weeks gestation; n = 24) and those experiencing SPTB (≤ 34 weeks gestation; n = 24).
RESULTS: We found 99 proteins that had statistically significant differences in signal intensity between term and SPTB women in both first (n = 26) and second (n = 22) singleton gestation pregnancy cohorts. Additional evaluation identified 18 biomarkers that met criteria for further priority evaluation (12 preterm, 6 term). Pathway analysis showed that differentiating SPTB biomarker proteins were predominantly associated with inflammation and cell injury, while differentiating term biomarkers were associated with cell growth and hematological parameters.
CONCLUSION: This study shows for the first time that the proteomic content of serum microparticles isolated in the second trimester can identify with a high degree of accuracy pregnancies that result in SPTB. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825961     DOI: 10.1055/s-0035-1547322

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  6 in total

1.  Evaluation of proteomic biomarkers associated with circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth.

Authors:  David E Cantonwine; Zhen Zhang; Kevin Rosenblatt; Kevin S Goudy; Robert C Doss; Alan M Ezrin; Gail Page; Brian Brohman; Thomas F McElrath
Journal:  Am J Obstet Gynecol       Date:  2016-02-11       Impact factor: 8.661

Review 2.  Translational Systems Pharmacology Studies in Pregnant Women.

Authors:  Sara K Quinney; Rakesh Gullapelli; David M Haas
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-12-14

3.  Effects of Selective Exclusion of Patients on Preterm Birth Test Performance.

Authors:  J Jay Boniface; Julja Burchard; George R Saade
Journal:  Obstet Gynecol       Date:  2019-12       Impact factor: 7.661

4.  Quantitative proteomic profiling of Cervicovaginal fluid from pregnant women with term and preterm birth.

Authors:  Young Eun Kim; Kwonseong Kim; Han Bin Oh; Sung Ki Lee; Dukjin Kang
Journal:  Proteome Sci       Date:  2021-02-15       Impact factor: 2.480

5.  Is there a maternal blood biomarker that can predict spontaneous preterm birth prior to labour onset? A systematic review.

Authors:  Kylie K Hornaday; Eilidh M Wood; Donna M Slater
Journal:  PLoS One       Date:  2022-04-04       Impact factor: 3.240

6.  Late first trimester circulating microparticle proteins predict the risk of preeclampsia < 35 weeks and suggest phenotypic differences among affected cases.

Authors:  Thomas F McElrath; David E Cantonwine; Kathryn J Gray; Hooman Mirzakhani; Robert C Doss; Najmuddin Khaja; Malik Khalid; Gail Page; Brian Brohman; Zhen Zhang; David Sarracino; Kevin P Rosenblatt
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.